Impact of non-canonical cysteine on the stability of monoclonal antibody therapeutics: implications for candidate selection
This study challenges the assumption that non-canonical cysteines in monoclonal antibodies inherently compromise stability by demonstrating that a specific HC109 cysteine remains stable due to its buried location in a beta-sheet, leading to a proposed framework for assessing developability risk based on structural context and solvent accessibility rather than automatic elimination.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the world of modern medicine, monoclonal antibodies are among the most powerful tools we have. These are proteins designed to seek out and neutralize specific threats in the body, such as viruses or cancer cells, acting with the precision of a guided missile. To be effective, these proteins must remain stable and intact from the moment they are manufactured until they are administered to a patient. If they begin to clump together, or aggregate, they can lose their ability to work and, worse, might trigger an unwanted immune response. One of the most common causes of this instability involves cysteine, a specific building block within the protein chain. Normally, cysteines pair up tightly with one another to form strong internal bridges called disulfide bonds, which hold the antibody's shape together. However, sometimes an antibody contains an extra cysteine in a place where it does not belong. Scientists have long worried that these "non-canonical" cysteines act like loose ends, prone to grabbing onto other molecules and causing the protein to fall apart or stick together in harmful clumps. Because of this risk, drug developers often discard any antibody candidate that carries one of these extra cysteines, assuming the molecule is too dangerous to use.
A team of researchers at BioTherapeutics Solutions decided to test whether this long-held assumption was always true. They focused on a specific antibody, named BTS mAb001, which contained one of these extra cysteines at a precise location on its heavy chain. Instead of immediately rejecting the molecule, they subjected it to rigorous testing to see how it behaved under stress. They placed the antibody in different liquid environments, some acidic and some neutral, and warmed them up to temperatures that would typically force proteins to degrade. They then watched closely to see if the molecules would clump together or if the extra cysteine would react with other parts of the protein. To their surprise, the antibody behaved with remarkable stability. Even after four weeks in warm, neutral conditions that usually cause trouble, the amount of clumping was no higher than what is seen in standard, well-behaved antibodies. The extra cysteine did not cause the molecule to fall apart.
The researchers then looked deeper to understand why this molecule was so resilient. They analyzed the chemical state of the extra cysteine and found that it was almost entirely covered by a small, protective tag called cysteinylation. This meant the reactive part of the cysteine was occupied and unable to grab onto other molecules. To see the physical reason behind this protection, the team used advanced computer modeling to build a three-dimensional map of the antibody's structure. The model revealed that the extra cysteine was tucked away inside a tightly folded, rigid section of the protein, much like a stone hidden deep within a rock formation. Because it was buried in this rigid structure, the sulfur atom at the heart of the cysteine had very little contact with the surrounding liquid, making it nearly impossible for it to form unwanted bonds. This was a stark contrast to other antibodies studied in the past, where similar extra cysteines were found in floppy, open loops that were exposed to the liquid, allowing them to react freely and cause clumping.
By comparing their findings with previous studies of other antibodies containing extra cysteines, the researchers began to see a clear pattern. The danger of an extra cysteine did not seem to come from its mere presence, but rather from where it was located and how exposed it was. When the extra cysteine was in a flexible, open area, it tended to cause aggregation. When it was locked away in a rigid, buried spot, as in their new antibody, it remained harmless. The team proposed a new way to evaluate future drug candidates. Instead of automatically discarding any antibody with an extra cysteine, developers could first use computer models to check if the cysteine is buried or exposed. If it is exposed, they can test it quickly to see if it causes clumping. If it is buried, the molecule might be safe to keep. This approach suggests that scientists can save time and resources by not throwing away potentially useful drugs based on a single feature, but rather by understanding the specific environment of that feature. The study indicates that with the right structural context, an antibody with an extra cysteine can be just as stable and safe as any other, opening the door to a wider range of therapeutic possibilities.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.